Shire signs strategic partnership deal with ICON

pharmafile | January 10, 2012 | News story | Research and Development ICON, Shire 

Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of central laboratory services, and one of two strategic partners for clinical development services. 

As a partner for clinical development, ICON will provide Shire with a full range of services including site and country feasibility, ethics and regulatory submissions, clinical trial monitoring, project management, site and study team support, medical management and medical data review. Shire will also utilise ICON Central Laboratories’ extensive test menu from its global network of laboratories.

“We are proud that Shire Specialty Pharmaceuticals has selected ICON as a global partner and it is yet another endorsement of ICON’s expertise in operating under strategic partnership models,” commented Ciaran Murray, chief executive of ICON.

Advertisement

“ICON’s success is based on the right blend of development services and global testing facilities, all of which are underpinned by robust processes and innovative technology. We look forward to building on our successful relationship with Shire to help them realise efficiencies as they seek to bring new products to market.”

Related Content

takeda_deerfield_hq

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …

novartis_window

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …

The Gateway to Local Adoption Series

Latest content